Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer.

British journal of cancer - 1 Jun 2023

Choi Yu-Ra, Kang Eun Hye, Kim Sunshin, Park Seog-Yun, Han Ji-Youn, Lee Youngjoo

Abstract excerpt

BACKGROUND: In EGFR-mutant and MET-amplified lung cancer resistant to EGFR inhibitors, double blockade of EGFR and MET is considered as a reasonable strategy despite increasing toxicity. This study evaluated the single MET inhibition in these specific tumours. METHODS: We investigated the efficacy of a single MET inhibitor in EGFR-mutant, MET-amplified lung cancer cells (HCC827GR) and the matched clinical cases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Gefitinib

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 37059804
DOI: 10.1038/s41416-023-02264-4
PMCID: PMC10241937

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer.PMID 37059804Read ↗

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer.Semantic proximity Read ↗

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.Semantic proximity Read ↗

Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.Semantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

Progress on treatment of MET signaling pathway in non-small cell lung cancer.Semantic proximity Read ↗

Met inhibitors in the treatment of lung cancer: the evidence to date.Semantic proximity Read ↗

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification.Semantic proximity Read ↗

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.Semantic proximity Read ↗

The coexistence of MET over-expression and an <i>EGFR</i> T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancerSemantic proximity Read ↗

Tracking MET de-addiction in lung cancer: A road towards the oncogenic target.Semantic proximity Read ↗

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.